×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XLO – xilio therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XLO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/8
01:44 pm
xlo
Xilio Therapeutics, Inc. (NASDAQ: XLO) had its price target lowered by analysts at Raymond James from $6.00 to $4.00. They now have an "outperform" rating on the stock.
Low
Report
Xilio Therapeutics, Inc. (NASDAQ: XLO) had its price target lowered by analysts at Raymond James from $6.00 to $4.00. They now have an "outperform" rating on the stock.
11/7
09:15 am
xlo
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
High
Report
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
11/7
09:09 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results [Yahoo! Finance]
11/7
09:05 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
High
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
10/30
09:01 am
xlo
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
High
Report
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
10/21
08:29 am
xlo
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4's NSCLC therapy [Yahoo! Finance]
Low
Report
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4's NSCLC therapy [Yahoo! Finance]
10/4
09:17 am
xlo
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting [Yahoo! Finance]
Medium
Report
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting [Yahoo! Finance]
10/4
09:05 am
xlo
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Medium
Report
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:44 pm
xlo
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.
High
Report
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.
11/14
04:31 pm
xlo
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Medium
Report
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
11/12
04:51 pm
xlo
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Rock Springs Capital Management LP
Medium
Report
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: Rock Springs Capital Management LP
11/12
10:41 am
xlo
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: FMR LLC
Low
Report
Form SC 13G/A Xilio Therapeutics, Inc. Filed by: FMR LLC
11/7
09:26 am
xlo
Form 10-Q Xilio Therapeutics, Inc. For: Sep 30
High
Report
Form 10-Q Xilio Therapeutics, Inc. For: Sep 30
11/7
09:21 am
xlo
Form 8-K Xilio Therapeutics, Inc. For: Nov 07
Medium
Report
Form 8-K Xilio Therapeutics, Inc. For: Nov 07
10/2
05:15 pm
xlo
Form 4 Xilio Therapeutics, Inc. For: Oct 01 Filed by: Brennan Kevin M.
Medium
Report
Form 4 Xilio Therapeutics, Inc. For: Oct 01 Filed by: Brennan Kevin M.
9/27
09:37 pm
xlo
Form SC 13G Xilio Therapeutics, Inc. Filed by: GKCC, LLC
Medium
Report
Form SC 13G Xilio Therapeutics, Inc. Filed by: GKCC, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: